Antibacterial Resistance Leadership Group 2.0: Back to Business

Henry F. Chambers; Scott R. Evans; Robin Patel; Heather R. Cross; Anthony D. Harris; Yohei Doi; Helen W. Boucher; David Van Duin; Ephraim L. Tsalik; Thomas L. Holland; Melinda M. Pettigrew; Pranita D. Tamma; Kathryn R. Hodges; Maria Souli; Vance G. Fowler

doi:10.1093/cid/ciab141

Antibacterial Resistance Leadership Group 2.0: Back to Business

Henry F. Chambers, Scott R. Evans, Robin Patel, Heather R. Cross, Anthony D. Harris, Yohei Doi, Helen W. Boucher, David Van Duin, Ephraim L. Tsalik, Thomas L. Holland, Melinda M. Pettigrew, Pranita D. Tamma, Kathryn R. Hodges, Maria Souli, Vance G. Fowler

Laboratory Medicine and Pathology

Research output: Contribution to journal › Review article › peer-review

Abstract

In December 2019, the Antibacterial Resistance Leadership Group (ARLG) was awarded funding for another 7-year cycle to support a clinical research network on antibacterial resistance. ARLG 2.0 has 3 overarching research priorities: infections caused by antibiotic-resistant (AR) gram-negative bacteria, infections caused by AR gram-positive bacteria, and diagnostic tests to optimize use of antibiotics. To support the next generation of AR researchers, the ARLG offers 3 mentoring opportunities: the ARLG Fellowship, Early Stage Investigator seed grants, and the Trialists in Training Program. The purpose of this article is to update the scientific community on the progress made in the original funding period and to encourage submission of clinical research that addresses 1 or more of the research priority areas of ARLG 2.0.

Original language	English (US)
Pages (from-to)	730-739
Number of pages	10
Journal	Clinical Infectious Diseases
Volume	73
Issue number	4
DOIs	https://doi.org/10.1093/cid/ciab141
State	Published - Aug 15 2021

Keywords

Antibacterial Resistance Leadership Group
clinical research
mentoring

ASJC Scopus subject areas

Microbiology (medical)
Infectious Diseases

Access to Document

10.1093/cid/ciab141

Cite this

@article{9e64cd3455c649f4b9350cbd005628c3,

title = "Antibacterial Resistance Leadership Group 2.0: Back to Business",

abstract = "In December 2019, the Antibacterial Resistance Leadership Group (ARLG) was awarded funding for another 7-year cycle to support a clinical research network on antibacterial resistance. ARLG 2.0 has 3 overarching research priorities: infections caused by antibiotic-resistant (AR) gram-negative bacteria, infections caused by AR gram-positive bacteria, and diagnostic tests to optimize use of antibiotics. To support the next generation of AR researchers, the ARLG offers 3 mentoring opportunities: the ARLG Fellowship, Early Stage Investigator seed grants, and the Trialists in Training Program. The purpose of this article is to update the scientific community on the progress made in the original funding period and to encourage submission of clinical research that addresses 1 or more of the research priority areas of ARLG 2.0.",

keywords = "Antibacterial Resistance Leadership Group, clinical research, mentoring",

author = "Chambers, {Henry F.} and Evans, {Scott R.} and Robin Patel and Cross, {Heather R.} and Harris, {Anthony D.} and Yohei Doi and Boucher, {Helen W.} and {Van Duin}, David and Tsalik, {Ephraim L.} and Holland, {Thomas L.} and Pettigrew, {Melinda M.} and Tamma, {Pranita D.} and Hodges, {Kathryn R.} and Maria Souli and Fowler, {Vance G.}",

note = "Publisher Copyright: {\textcopyright} 2021 The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.",

year = "2021",

month = aug,

day = "15",

doi = "10.1093/cid/ciab141",

language = "English (US)",

volume = "73",

pages = "730--739",

journal = "Clinical Infectious Diseases",

issn = "1058-4838",

publisher = "Oxford University Press",

number = "4",

}

TY - JOUR

T1 - Antibacterial Resistance Leadership Group 2.0

T2 - Back to Business

AU - Chambers, Henry F.

AU - Evans, Scott R.

AU - Patel, Robin

AU - Cross, Heather R.

AU - Harris, Anthony D.

AU - Doi, Yohei

AU - Boucher, Helen W.

AU - Van Duin, David

AU - Tsalik, Ephraim L.

AU - Holland, Thomas L.

AU - Pettigrew, Melinda M.

AU - Tamma, Pranita D.

AU - Hodges, Kathryn R.

AU - Souli, Maria

AU - Fowler, Vance G.

N1 - Publisher Copyright: © 2021 The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

PY - 2021/8/15

Y1 - 2021/8/15

N2 - In December 2019, the Antibacterial Resistance Leadership Group (ARLG) was awarded funding for another 7-year cycle to support a clinical research network on antibacterial resistance. ARLG 2.0 has 3 overarching research priorities: infections caused by antibiotic-resistant (AR) gram-negative bacteria, infections caused by AR gram-positive bacteria, and diagnostic tests to optimize use of antibiotics. To support the next generation of AR researchers, the ARLG offers 3 mentoring opportunities: the ARLG Fellowship, Early Stage Investigator seed grants, and the Trialists in Training Program. The purpose of this article is to update the scientific community on the progress made in the original funding period and to encourage submission of clinical research that addresses 1 or more of the research priority areas of ARLG 2.0.

AB - In December 2019, the Antibacterial Resistance Leadership Group (ARLG) was awarded funding for another 7-year cycle to support a clinical research network on antibacterial resistance. ARLG 2.0 has 3 overarching research priorities: infections caused by antibiotic-resistant (AR) gram-negative bacteria, infections caused by AR gram-positive bacteria, and diagnostic tests to optimize use of antibiotics. To support the next generation of AR researchers, the ARLG offers 3 mentoring opportunities: the ARLG Fellowship, Early Stage Investigator seed grants, and the Trialists in Training Program. The purpose of this article is to update the scientific community on the progress made in the original funding period and to encourage submission of clinical research that addresses 1 or more of the research priority areas of ARLG 2.0.

KW - Antibacterial Resistance Leadership Group

KW - clinical research

KW - mentoring

UR - http://www.scopus.com/inward/record.url?scp=85114294707&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85114294707&partnerID=8YFLogxK

U2 - 10.1093/cid/ciab141

DO - 10.1093/cid/ciab141

M3 - Review article

C2 - 33588438

AN - SCOPUS:85114294707

SN - 1058-4838

VL - 73

SP - 730

EP - 739

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

IS - 4

ER -

Antibacterial Resistance Leadership Group 2.0: Back to Business

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this